Grifols (GIFLF) Cash from Operations Growth (3y) (2013 - 2022)
Powered by 
Analysis
Grifols (GIFLF) Cash from Operations Growth (3y) (2013 - 2022) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | -0.88% |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 15.19% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | -0.27% |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | -7.35% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 16.85% |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 96.08% |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -2.68% |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | -26.07% |
| Mar 31, 2020 | -9.10% |
| Dec 31, 2019 | 24.45% |
| Dec 31, 2018 | 11.10% |
| Jun 30, 2018 | -8.83% |
| Mar 31, 2018 | 43.48% |
| Dec 31, 2017 | 18.50% |
| Jun 30, 2017 | 51.85% |
| Mar 31, 2017 | -3.27% |
| Dec 31, 2016 | -14.17% |
| Sep 30, 2016 | 26.64% |
| Dec 31, 2015 | 18.18% |
| Sep 30, 2015 | 5.26% |
| Jun 30, 2015 | 12.50% |
| Mar 31, 2015 | -28.31% |
| Dec 31, 2014 | 23.44% |
| Sep 30, 2014 | 140.41% |
| Jun 30, 2014 | -63.92% |
| Mar 31, 2014 | 42.06% |
| Dec 31, 2013 | 91.29% |